Sheckter Clifford C, Panchal Hina J, Razdan Shantanu N, Rubin David, Yi Day, Disa Joseph J, Mehrara Babak, Matros Evan
From the Division of Plastic and Reconstructive Surgery and the Clinical Excellence Research Center, Stanford University; and the Plastic and Reconstructive Surgery Service and Managed Care, Planning and Analysis Group, Memorial Sloan Kettering Cancer Center.
Plast Reconstr Surg. 2018 Oct;142(4):434e-442e. doi: 10.1097/PRS.0000000000004727.
Flap-based breast reconstruction demands greater operative labor and offers superior patient-reported outcomes compared with implants. However, use of implants continues to outpace flaps, with some suggesting inadequate remuneration as one barrier. This study aims to characterize market variation in the ratio of implants to flaps and assess correlation with physician payments.
Using the Blue Health Intelligence database from 2009 to 2013, patients were identified who underwent tissue expander (i.e., implant) or free-flap breast reconstruction. The implant-to-flap ratio and physician payments were assessed using quadratic modeling. Matched bootstrapped samples from the early and late periods generated probability distributions, approximating the odds of surgeons switching reconstructive method.
A total of 21,259 episodes of breast reconstruction occurred in 122 U.S. markets. The distribution of implant-to-flap ratio varied by market, ranging from the fifth percentile at 1.63 to the ninety-fifth percentile at 43.7 (median, 6.19). Modeling the implant-to-flap ratio versus implant payment showed a more elastic quadratic equation compared with the function for flap-to-implant ratio versus flap payment. Probability modeling demonstrated that switching the reconstructive method from implants to flaps with a 0.75 probability required a $1610 payment increase, whereas switching from flaps to implants at the same certainty occurred at a loss of $960.
There was a correlation between the ratio of flaps to implants and physician reimbursement by market. Switching from implants to flaps required large surgeon payment increases. Despite a relative value unit schedule over twice as high for flaps, current flap reimbursements do not appear commensurate with physician effort.
与乳房植入物相比,皮瓣乳房重建手术需要更多的手术操作,且患者报告的结局更佳。然而,植入物的使用量仍超过皮瓣,有人认为报酬不足是一个障碍。本研究旨在描述植入物与皮瓣比例的市场差异,并评估与医生报酬的相关性。
利用2009年至2013年的蓝色健康情报数据库,识别接受组织扩张器(即植入物)或游离皮瓣乳房重建的患者。使用二次模型评估植入物与皮瓣的比例以及医生报酬。从早期和晚期匹配的自抽样样本生成概率分布,近似外科医生转换重建方法的可能性。
美国122个市场共发生21259例乳房重建事件。植入物与皮瓣比例的分布因市场而异,从第5百分位数的1.63到第95百分位数的43.7(中位数为6.19)。对植入物与皮瓣比例与植入物报酬进行建模,结果显示与皮瓣与植入物比例与皮瓣报酬的函数相比,二次方程的弹性更大。概率建模表明,以0.75的概率将重建方法从植入物转换为皮瓣需要增加1610美元的报酬,而在相同确定性下从皮瓣转换为植入物则会损失960美元。
皮瓣与植入物的比例与市场医生报销之间存在相关性。从植入物转换为皮瓣需要大幅提高外科医生的报酬。尽管皮瓣的相对价值单位计划高出两倍多,但目前皮瓣的报销似乎与医生的工作量不相称。